Navigation Links
Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
Date:8/31/2013

or symptoms of blood loss (e.g., a drop in hemoglobin and/or hematocrit or hypotension). Discontinue PRADAXA in patients with active pathological bleeding.
  • Risk factors for bleeding include concomitant use of medications that increase the risk of bleeding (e.g., anti-platelet agents, heparin, fibrinolytic therapy, and chronic use of NSAIDs). PRADAXA's anticoagulant activity and half-life are increased in patients with renal impairment.
  • A specific reversal agent for dabigatran is not available. Hemodialysis can remove dabigatran; however clinical experience for hemodialysis as a treatment for bleeding is limited. Activated prothrombin complex concentrates, recombinant Factor VIIa, or concentrates of factors II, IX or X may be considered but their use has not been evaluated. Protamine sulfate and vitamin K are not expected to affect dabigatran anticoagulant activity. Consider administration of platelet concentrates where thrombocytopenia is present or long-acting antiplatelet drugs have been used.
  • Thromboembolic and Bleeding Events in Patients with Prosthetic Heart Valves
    The safety and efficacy of PRADAXA in patients with bileaflet mechanical prosthetic heart valves (recently implanted or implanted more than 3 months prior to enrollment) was evaluated in the phase 2 RE-ALIGN trial. RE-ALIGN was terminated early because of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) for PRADAXA vs warfarin. Therefore, the use of PRADAXA is contraindicated in patients with mechanical prosthetic valves.

    Use of PRADAXA for the prophylaxis of thromboembolic events in patients with AFib in the setting of other forms of valvular heart disease, including bioprosthetic heart valve, has not been studied and is not recommended.

    Ef
    '/>"/>

    SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
    2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
    3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
    4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
    5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
    6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
    7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
    8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
    9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
    10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
    11. Boehringer Ingelheim Announces Equine Research Awards
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... , July 10, 2014 CVS Caremark Corporation (NYSE: ... directors has approved a quarterly dividend of $0.275 (27.5 cents) ... payable on August 1, 2014, to holders of record on ... CVS Caremark is dedicated to helping people on their ... in the United States . Through the ...
    (Date:1/15/2014)... and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition ... Analysis, Size, Share, Growth, Trends And Forecast, 2013 - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Dental ... order to treat dental impairments, for tooth restoration and ...
    (Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
    Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
    ... Semafore Pharmaceuticals Inc.,announced today on the occasion of ... Conference in San Francisco that its,integrin-targeted PI3 kinase ... agents in vitro and in vivo (poster,C207). ... of prostate cancer cells with combinations of docetaxel ...
    ... IRVINE, Calif., Oct. 26 IDM Pharma, Inc.,(Nasdaq: ... the development of,innovative cancer therapies, today announced details ... pipeline compounds to be,presented at upcoming medical congresses. ... Mifamurtide (L-MTP-PE):, Connective Tissue Oncology Society (CTOS) ...
    Cached Medicine Technology:Semafore's PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents 2IDM Pharma Announces Upcoming Clinical Data Presentations 2IDM Pharma Announces Upcoming Clinical Data Presentations 3IDM Pharma Announces Upcoming Clinical Data Presentations 4
    (Date:7/10/2014)... July 10, 2014 One week ahead ... Worker Safety announced today it will extend compensation benefits ... months’ wages for workers displaced as a result of ... Alliance inspections have resulted in the closure of five ... five cases, raising immediate safety concerns. In May, the ...
    (Date:7/10/2014)... 2014 According to a new ... Platforms (Land, Airborne, Naval), Application (Software Defined Radios, ... Geography (North America, Asia-Pacific, Europe, the Middle East ... by MarketsandMarkets, the market is estimated to be ... register a CAGR of 5.56% to reach $39.52 ...
    (Date:7/10/2014)... In his latest blog post at http://www.perwickstrom.com , ... Wickstrom has listed 5 ways to follow-up without being ... get information or sometimes even just return an inquiry, ... a skill that most people don’t have,” commented Per ... dialogue moving without coming across as annoying – let ...
    (Date:7/10/2014)... Creek, MI (PRWEB) July 10, 2014 ... alcohol treatment program that gets clients off to a ... recovery they can believe in, has launched a new ... , The new section highlights:, , ... Diagnostic and Statistic Manual of Mental Disorders (DSM-IV), including ...
    (Date:7/10/2014)... (PRWEB) July 10, 2014 Ivalua, ... latest results of the 4th “Trending in Procurement” ... model. , Every day multinational corporations process ... expense forms etc. To meet this challenge, more ... suites which can be defined as a suite ...
    Breaking Medicine News(10 mins):Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Per Wickstrom’s Latest Blog Post Lists 5 Ways to Follow-up Without Being Annoying 2Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 3
    ... Hospitality Solutions with Pro:Idiom , Enable MSOs to ... R.L. Drake , an American ... highly innovative communications solutions for over 65 years, has ... cable transcoders to cable operators in the United States ...
    ... April 1, GlaxoSmithKline (NYSE: GSK ... regulatory applications to expand the use of TYVERB(R)/TYKERB(R) ... as a first-line therapy regimen combined with anti-hormonal ... breast cancer in Europe and the United States.The ...
    ... low-level shoulder separations can commonly be treated nonsurgically and ... in the April 2009 issue of the Journal ... JAAOS ) finds that many surgeons still disagree on ... fall in between. , , Shoulder separations, clinically ...
    ... an important contribution to future clinical therapeutic approaches. The ... Nature and will be a central topic of ... which will take place in Munich from April 2nd ... mechanisms of blood formation (hematopoiesis) will be presented in ...
    ... Organization for disAbilities Resources champions company,s effortsGAITHERSBURG, Md., ... Disability Matters Award in the category of Work ... supporting people with disabilities and their families. The ... and Springboard Consulting. The integrated food and facilities ...
    ... mid-level, common injury ROSEMONT, Ill., April 1 While low-level shoulder ... surgery, a literature review published in the April 2009 issue of ... ( JAAOS ) finds that many surgeons still disagree ... in between., , ...
    Cached Medicine News:Health News:Drake Nabs 'Suite Deal' as Distributor of Pro:Idiom(R) Hospitality Solution to U.S. and Canadian Cable Operators 2Health News:GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, US 2Health News:GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, US 3Health News:GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, US 4Health News:GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, US 5Health News:Healing a shoulder separation 2Health News:Last step leading to blood cell formation elucidated 2Health News:Sodexo Receives 2009 Disability Matters Award 2Health News:Sodexo Receives 2009 Disability Matters Award 3Health News:Healing a Shoulder Separation 2Health News:Healing a Shoulder Separation 3
    ... lab with the OLA2500 High Speed Sorter ... sorting requirements. As a front-end sample-processor, the ... primary sample tubes to their destination racks ... eliminate sample-handling errors. Post-analytical archiving to any ...
    Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
    Similar to Model 530, but just 37 inches long and with only one drape....
    2-ply material consisting of polyethylene film inner layer and non-woven outer layers....
    Medicine Products: